CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 185 enrolled
Drug / intervention
Intranasal Tear Neurostimulatordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02910713
NCT02910713N/ACompleted

Multicenter, Randomized, Controlled, Single-Masked, Cross-Over Clinical Trial to Evaluate Dry Eye Symptoms With Application of the Oculeve Intranasal Tear Neurostimulator During Exposure to a Controlled Adverse Environment (CAE®)

Allergan·interventional·Posted Sep 22, 2016·Updated Jan 31, 2020

In Brief

A clinical study evaluating Intranasal Tear Neurostimulator for Dry Eye Syndromes. Completed, enrolled 185 participants across 3 sites.

Detailed Summary

This study evaluates the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally (active) compared with the same device applied extranasally (control) relating to symptoms of dry eye exacerbated by the Controlled Adverse Environment model.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedSep 22, 2016
Enrollment StartSep 30, 2016
Primary CompletionOct 31, 2016
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 9.8 years ago

Interventions

Intranasal Tear Neurostimulatordevice

The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.